STATISTICAL SUPPORT UNIT
统计支持单位
基本信息
- 批准号:7515853
- 负责人:
- 金额:$ 92.1万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-09-14 至 2012-05-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdverse eventBiostatistics Shared ResourceBooksCancer ControlCase Report FormClinicClinical ResearchClinical TrialsClinical Trials Data Monitoring CommitteesCollaborationsCommon Data ElementDataData CollectionDatabasesDevelopmentDoctor of PhilosophyElectronicsFactor AnalysisGenerationsGoalsHuman ResourcesIndividualInformation SystemsInformation TechnologyLeadershipMaintenanceMalignant NeoplasmsManualsMayo Clinic Cancer CenterMonitorNorth Central Cancer Treatment GroupOnline SystemsOperative Surgical ProceduresPathologyPatientsProtocols documentationQuality ControlRandomizedRecordsReportingResource SharingRoleSample SizeSchemeSerious Adverse EventSpecialistSpecific qualifier valueStratification FactorsSubgroupSystemTrainingTranslational Researchconceptdata managementdesigninstrumentmemberprogramsstatistics
项目摘要
2.6.3.3 NCCTG Statistical Data Center
The NCCTG Statistical Data Center (SDC), under the direction of the Group Statistician, Daniel J. Sargent,
Ph.D., is comprised of two units: the Statistics Unit and the Data Systems Unit. The two units function in a
highly coordinated fashion under the leadership of Dr. Sargent and the Group Operations Coordinator.
Together, these two units provide statistical collaboration, data management support, and information
technology (IT) support for the development and conduct of NCCTG cancer clinical trials, including
translational research.
The Statistics Unit exists within the Mayo Clinic Cancer Center (MCCC) Biostatistics Shared Resource, also
directed by Dr. Sargent, where statistical support for multiple programs provides synergies that benefit all.
There are over 40 individuals currently in this shared resource. The NCCTG Statistics Unit currently consists
of portions of 8 Ph.D statisticians, 9 master trained statisticians, 10 statistical programmer analysts (SPAs).and
2 administrative assistants.
The Data Systems Unit, under the direction of Ms. Paulson, exists within the MCCC Clinical Research Office
Shared Resource that includes over 140 individuals. Again, the high degree of interaction provides synergies
that benefit all. The NCCTG Data Systems Unit is comprised of three subgroups:
1. Programming Unit with 17 Analyst/Programmers.
2. Data Coordination Unit with 4 Data Management Specialists and 1 Administrative Assistant.
3. Clinical Trials Coordination that includes the Quality Control Unit, the Randomization Unit, and the
Compliance Unit. The Quality Control Unit includes 18 Quality Control Specialists,'the NCCTG SAE
Coordinator, the NCCTG Pathology Coordinator, the NCCTG Surgery Coordinator, and 1 supervisor.
The Randomization Unit includes 3 Randomization Specialists. The Compliance Unit includes 2
Compliance Specialists. While the personnel within the Compliance Unit are considered members of
the Data Systems Unit, their activities are defined by the NCCTG Audit Committee.
2.6.3.3 NCCTG统计数据中心
NCCTG统计数据中心(SDC),由集团统计学家丹尼尔·J·萨金特领导,
博士学位由两个单位组成:统计股和数据系统股。这两个单元在一个
在萨金特博士和集团业务协调员的领导下,高度协调。
这两个单位共同提供统计协作、数据管理支持和信息
为NCCTG癌症临床试验的开发和实施提供技术(IT)支持,包括
翻译研究。
统计股存在于梅奥诊所癌症中心(MCCC)生物统计共享资源内,还
由萨金特博士指导,其中对多个项目的统计支持提供了协同效应,使所有人都受益。
这个共享资源中目前有40多个人。NCCTG统计股目前由
在8名博士统计员中,9名受过硕士培训的统计员,10名统计程序分析员(SPA)。
2名行政助理。
数据系统股在保尔森女士的领导下,设在MCCC临床研究办公室内
包括140多个人的共享资源。同样,高度的互动提供了协同效应
这对所有人都有利。NCCTG数据系统股由三个小组组成:
1.编程股有17名分析员/编程员。
2.数据协调股,有4名数据管理专家和1名行政助理。
3.临床试验协调,包括质量控制股、随机股和
合规部。质量控制部门包括18名质量控制专家,NCCTG SAE
协调员、NCCTG病理协调员、NCCTG手术协调员和1名主管。
随机股包括3名随机化专家。合规股包括2个
合规专家。虽然合规股内的人员被认为是
数据系统股,其活动由NCCTG审计委员会定义。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CHARLES L LOPRINZI其他文献
CHARLES L LOPRINZI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CHARLES L LOPRINZI', 18)}}的其他基金
Survivorship research established investigator award
生存研究设立研究者奖
- 批准号:
7826598 - 财政年份:2008
- 资助金额:
$ 92.1万 - 项目类别:
Survivorship research established investigator award
生存研究设立研究者奖
- 批准号:
7466151 - 财政年份:2008
- 资助金额:
$ 92.1万 - 项目类别:
Survivorship research established investigator award
生存研究设立研究者奖
- 批准号:
8078080 - 财政年份:2008
- 资助金额:
$ 92.1万 - 项目类别:
Survivorship research established investigator award
生存研究设立研究者奖
- 批准号:
8282597 - 财政年份:2008
- 资助金额:
$ 92.1万 - 项目类别:
Survivorship research established investigator award
生存研究设立研究者奖
- 批准号:
7629717 - 财政年份:2008
- 资助金额:
$ 92.1万 - 项目类别:
相似海外基金
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10707830 - 财政年份:2023
- 资助金额:
$ 92.1万 - 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
- 批准号:
479728 - 财政年份:2023
- 资助金额:
$ 92.1万 - 项目类别:
Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
- 批准号:
10884567 - 财政年份:2023
- 资助金额:
$ 92.1万 - 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
- 批准号:
10751964 - 财政年份:2023
- 资助金额:
$ 92.1万 - 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
- 批准号:
486321 - 财政年份:2022
- 资助金额:
$ 92.1万 - 项目类别:
Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10676786 - 财政年份:2022
- 资助金额:
$ 92.1万 - 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10440970 - 财政年份:2022
- 资助金额:
$ 92.1万 - 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
- 批准号:
10642998 - 财政年份:2022
- 资助金额:
$ 92.1万 - 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10482465 - 财政年份:2022
- 资助金额:
$ 92.1万 - 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
- 批准号:
10191053 - 财政年份:2020
- 资助金额:
$ 92.1万 - 项目类别: